{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:59:40Z","timestamp":1780059580216,"version":"3.54.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,3]]},"DOI":"10.7759\/cureus.106386","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:54:33Z","timestamp":1775235273000},"source":"Crossref","is-referenced-by-count":1,"title":["Severe Treatment-Refractory Macrophage Activation Syndrome-Hemophagocytic Lymphohistiocytosis Presenting With Neurologic Crisis in Systemic Lupus Erythematosus"],"prefix":"10.7759","author":[{"given":"Zehra","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Scotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Watford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Woodbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabeer","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maleeha","family":"Abedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2314005","article-title":"Hemophagocytic lymphohistiocytosis","volume":"392","author":"Henter JI","year":"2025","unstructured":"Henter JI. Hemophagocytic lymphohistiocytosis. N Engl J Med. 2025, 392:584-98. 10.1056\/NEJMra2314005","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet L","year":"2014","unstructured":"Fardet L, Galicier L, Lambotte O, et al.. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014, 66:2613-20. 10.1002\/art.38690","journal-title":"Arthritis Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis A","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, et al.. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024, 83:15-29. 10.1136\/ard-2023-224762","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27929","article-title":"Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO)","volume":"66","author":"Jordan MB","year":"2019","unstructured":"Jordan MB, Allen CE, Greenberg J, et al.. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019, 66:e27929. 10.1002\/pbc.27929","journal-title":"Pediatr Blood Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0000000000000078","article-title":"Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis\/sepsis\/multiple organ dysfunction\/macrophage activating syndrome in critically ill children*","volume":"15","author":"Rajasekaran S","year":"2014","unstructured":"Rajasekaran S, Kruse K, Kovey K, et al.. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis\/sepsis\/multiple organ dysfunction\/macrophage activating syndrome in critically ill children*. Pediatr Crit Care Med. 2014, 15:401-8. 10.1097\/PCC.0000000000000078","journal-title":"Pediatr Crit Care Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-025-07420-0","article-title":"Characterization of patients with macrophage activation syndrome secondary to systemic juvenile idiopathic arthritis","volume":"44","author":"Rogowska J","year":"2025","unstructured":"Rogowska J, Kubicka J, Grabowska M, Mirocha G, Roszkiewicz J, Smolewska E. Characterization of patients with macrophage activation syndrome secondary to systemic juvenile idiopathic arthritis. Clin Rheumatol. 2025, 44:2023-9. 10.1007\/s10067-025-07420-0","journal-title":"Clin Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11140","article-title":"Intravenous anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of coronavirus disease 2019","volume":"2","author":"Wampler Muskardin TL","year":"2020","unstructured":"Wampler Muskardin TL. Intravenous anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of coronavirus disease 2019. ACR Open Rheumatol. 2020, 2:283-5. 10.1002\/acr2.11140","journal-title":"ACR Open Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta P","year":"2020","unstructured":"Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020, 2:e358-67. 10.1016\/S2665-9913(20)30096-5","journal-title":"Lancet Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224123","article-title":"The 2022 EULAR\/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS)","volume":"82","author":"Shakoory B","year":"2023","unstructured":"Shakoory B, Geerlinks A, Wilejto M, et al.. The 2022 EULAR\/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS). Ann Rheum Dis. 2023, 82:1271-85. 10.1136\/ard-2023-224123","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.10.1635","article-title":"Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance","volume":"10","author":"Lum BL","year":"1992","unstructured":"Lum BL, Kaubisch S, Yahanda AM, et al.. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol. 1992, 10:1635-42. 10.1200\/JCO.1992.10.10.1635","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302282","article-title":"Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis","volume":"192","author":"Johnson TS","year":"2014","unstructured":"Johnson TS, Terrell CE, Millen SH, Katz JD, Hildeman DA, Jordan MB. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol. 2014, 192:84-91. 10.4049\/jimmunol.1302282","journal-title":"J Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2015.1.190","article-title":"Treatment of hemophagocytic lymphohistiocytosis in adults","volume":"2015","author":"La Ros\u00e9e P","year":"2015","unstructured":"La Ros\u00e9e P. Treatment of hemophagocytic lymphohistiocytosis in adults. Hematology Am Soc Hematol Educ Program. 2015, 2015:190-6. 10.1182\/asheducation-2015.1.190","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli F","year":"2020","unstructured":"Locatelli F, Jordan MB, Allen C, et al.. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020, 382:1811-22. 10.1056\/NEJMoa1911326","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002289","article-title":"Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis","volume":"134","author":"Vallurupalli M","year":"2019","unstructured":"Vallurupalli M, Berliner N. Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis. Blood. 2019, 134:1783-6. 10.1182\/blood.2019002289","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/445020-severe-treatment-refractory-macrophage-activation-syndrome-hemophagocytic-lymphohistiocytosis-presenting-with-neurologic-crisis-in-systemic-lupus-erythematosus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:54:34Z","timestamp":1775235274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/445020-severe-treatment-refractory-macrophage-activation-syndrome-hemophagocytic-lymphohistiocytosis-presenting-with-neurologic-crisis-in-systemic-lupus-erythematosus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.106386","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,3]]}}}